Ranbaxy launches cholesterol-lowering drug `Atorvastatin’ in Europe
06 Mar 2012
Ranbaxy Laboratories Limited has launched the generic versions of Atorvastatin tablets, 10mg, 20mg, 40mg and 80mg in Germany, Italy and Sweden and 10mg, 20mg and 40mg in the Netherlands, after receiving approval from the respective local regulatory authorities.
The German subsidiary of Ranbaxy Laboratories Limited, Basics GmbH, today launched Atorvastatin Basics tablets in the German market.
Gurgaon-based Ranbaxy had obtained the rights to an early entry of Atorvastatin, the generic equivalent of Pfizer's cholesterol-lowering drug Sortis, in the European market through a settlement agreement with Pfizer.
Pfizer's patent for Sortis expires in the Netherlands and Sweden on 6 May, in Germany on 7 May and in Italy on 8 May 2012, Ranbaxy said in separate releases.
Ranbaxy said Basics GmbH, based in Leverkusen and its affiliate in Germany, Daiichi Sankyo Deutschland GmbH, will assist in the launch of the drug.
Daiichi Sankyo has a substantial reach amongst cardiologists and physicians, in the German market, Ranbaxy said.
.webp)
